Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Rhea-AI Summary
Tenax Therapeutics (NASDAQ: TENX) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. The company's presentation is a fireside chat on November 10, 2025 at 4:00 p.m. ET, featuring Chris Giordano, President & Chief Executive Officer, and Stuart Rich, M.D., Chief Medical Officer. A live webcast and archived replay will be available on the company's investor relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TENX declined 2.32%, reflecting a moderate negative market reaction. This price movement removed approximately $777K from the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.
Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: November 10, 2025, at 4:00 p.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com